Featured Research

from universities, journals, and other organizations

New drug candidate starves dormant cancer cells

Date:
February 18, 2014
Source:
Karolinska Institutet
Summary:
In solid tumors larger than a few millimetres, there is usually a lack of both oxygen and nutrients due to insufficient blood vessel growth. This in turn results in cancer cells falling into a state of dormancy. After treatment, such dormant cells will start to divide and tumors will grow. A new drug candidate selectively kills dormant cells within a cancer tumor through starvation. These tumor cells, which are found in less oxygenated parts of solid tumors, are resistant to conventional treatments.

In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. These tumour cells, which are found in less oxygenated parts of solid tumours, are resistant to conventional treatments.

In solid tumours larger than a few millimetres, there is usually a lack of both oxygen and nutrients due to insufficient blood vessel growth. This in turn results in cancer cells falling into a state of dormancy. After treatment, such dormant cells will start to divide and tumours will grow. This phenomenon therefore contributes to resistance of solid tumour to radio- and chemotherapy.

In their newly published study, the researchers show that cancer cells located in tumour regions that are poorly oxygenated and lack nutrition are unable to compensate for deficient mitochondrial energy production.

"We have identified a small molecule that we call VLX600, which in various in vitro and in vivo models has proven effective against dormant colon cancer cells that are otherwise very difficult to treat. VLX600 is a mild inhibitor of mitochondrial respiration, and we have found that dormant cancer cells have a limited possibility to compensate decreased mitochondrial function by increased glycolysis. The dormant cancer cells therefore die by starvation" says Stig Linder, the professor of experimental oncology leading the study.

The VLX600 molecule has been developed in cooperation with Uppsala-based biotech company Vivolux AB, where Stig Linder is also a board member. A clinical study of the substance in collaboration with American researchers is planned to take place this year. The research has been funded by grants from the Swedish Cancer Society, the Cancer Research Foundations of Radiumhemmet, the Swedish Research Council, the Alex and Eva Wallström Foundation and Swedish Foundation for Strategic Research.


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Xiaonan Zhang, Mårten Fryknäs, Emma Hernlund, Walid Fayad, Angelo De Milito, Maria Hägg Olofsson, Vladimir Gogvadze, Long Dang, Sven Påhlman, Leoni A. Kunz Schughart, Linda Rickardson, Padraig D′Arcy, Joachim Gullbo, Peter Nygren, Rolf Larsson, Stig Linder. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications, 2014; 5 DOI: 10.1038/ncomms4295

Cite This Page:

Karolinska Institutet. "New drug candidate starves dormant cancer cells." ScienceDaily. ScienceDaily, 18 February 2014. <www.sciencedaily.com/releases/2014/02/140218114121.htm>.
Karolinska Institutet. (2014, February 18). New drug candidate starves dormant cancer cells. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2014/02/140218114121.htm
Karolinska Institutet. "New drug candidate starves dormant cancer cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140218114121.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) — New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins